ANZ Healthcare "What does UBS Evidence Lab's 5th GLP-1 survey show for..."

Research evidence excerpt

ANZ Healthcare "What does UBS Evidence Lab's 5th GLP-1 survey show for..."

Powered by Lab Global17 JulyResearch2026ab Evidence UBS YES

ANZ Healthcare Equities

AustralasiaWhat does UBS Evidence Lab's 5th GLP-1 survey

show for OSA? Healthcare

Marcus Curley

Analyst

marcus.curley@ubs.com

5th GLP-1 survey points to ongoing stimulus for CPAP starts... +64-9-913 4750

The 5th UBS Evidence Lab GLP-1 survey was recently fielded in the US across 500 GLP-1 David Low

current or past users. Obstructive sleep apnea (OSA) prevalence remained high at 33% Analyst

of respondents reflecting an average weight of 237 lbs (108 kgs), estimated BMI of 38 david.low@ubs.com

(vs US adult average of ~30) and associated comorbidities. In line with previous surveys, +61-2-9324 2843

16% of GLP-1 users are likely new OSA patients. This implies joint GLP-1 and CPAP starts James Meares

in US increased from 0.5m in 2024 to 1.0m by 2025, underpinned by US GLP-1 users Analyst

increasing from 6m to 10m helped by wider Medicare reimbursement, introduction of james.meares@ubs.com

oral GLP-1s and direct-to-consumer advertising. +61-29-324 3575

…partly countered by modest weight loss during use & elimination of OSA...

75% of respondents were current users with 82% (down from 87% across Wave 1-5)

covered by health insurance with an average co-payment of US$44 per prescription.

61% reported a reduction in calories intake vs 10% reporting an increase, resulting in an

average reduction in weight of 14%. This is better than weight reduction of 12% across

Wave 1-5, and potentially reflects more effective new GLP-1 drugs. The average BMI

reduction from 38 to 34 implies AHI falls from 47 events/hr to 31 events/hr (based on

Wisconsin Sleep Cohort study) for current GLP-1 users. Our BMI segmentation analysis